USMLE Step 2 Quiz: Coagulation And Bleeding Disorders

What this quiz covers

This quiz focuses on Coagulation And Bleeding Disorders, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 2.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Protamine sulfate
2. Vitamin K
3. Idarucizumab
4. Andexanet alfa (correct answer)

Explanation: Apixaban is a direct oral anticoagulant that acts as a Factor Xa inhibitor. In cases of life-threatening bleeding, specific reversal is indicated. Andexanet alfa is a recombinant modified factor Xa protein that acts as a decoy, binding to and sequestering Factor Xa inhibitors, thereby restoring the activity of endogenous Factor Xa. Protamine sulfate reverses heparin. Vitamin K reverses warfarin. Idarucizumab is the specific reversal agent for dabigatran, a direct thrombin inhibitor.

Question 2

1. Vitamin K
2. Desmopressin (DDAVP) (correct answer)
3. Platelet transfusion
4. Fresh frozen plasma

Explanation: Patients with chronic kidney disease and uremia develop a qualitative platelet defect (uremic platelet dysfunction), characterized by impaired platelet adhesion and aggregation. This occurs despite a typically normal platelet count and coagulation panel. The most appropriate first-line pharmacologic agent for treating or preventing bleeding in this setting is desmopressin (DDAVP), which increases the release of factor VIII and von Willebrand factor from endothelial cells, improving platelet function. Dialysis is also a key intervention to reduce uremic toxins. Platelet transfusions are generally ineffective as the transfused platelets quickly become dysfunctional in the uremic environment.

Question 3

1. Packed red blood cells
2. Fresh frozen plasma
3. Cryoprecipitate (correct answer)
4. Platelets

Explanation: The patient has a complex coagulopathy from liver failure, including a critically low fibrinogen level (hypofibrinogenemia), which contributes significantly to his bleeding. Cryoprecipitate is the blood product that contains the most concentrated source of fibrinogen. It also contains factor VIII, factor XIII, and von Willebrand factor. While fresh frozen plasma (FFP) contains all clotting factors including fibrinogen, it is not as concentrated, and large volumes would be required to significantly raise the fibrinogen level. Packed red blood cells and platelets do not contain significant amounts of fibrinogen.

Question 4

1. Infusion of recombinant factor IX concentrate (correct answer)
2. Infusion of cryoprecipitate
3. Administration of desmopressin (DDAVP)
4. Administration of fresh frozen plasma

Explanation: This patient has hemophilia B, which is a deficiency of factor IX. He is presenting with an acute hemarthrosis, a common and serious complication. The cornerstone of management is prompt replacement of the deficient clotting factor. Therefore, infusion of recombinant factor IX concentrate is the most appropriate and specific treatment. Cryoprecipitate is rich in factor VIII, vWF, and fibrinogen, but not factor IX. Desmopressin is used for mild hemophilia A and vWD but is not effective for hemophilia B. FFP contains factor IX but is not concentrated, requiring large volumes, and is not the standard of care when specific factor concentrates are available.

Question 5

1. Vitamin K (correct answer)
2. Factor VIII
3. Platelets
4. Fibrinogen

Explanation: This clinical scenario is classic for vitamin K deficiency bleeding (VKDB) of the newborn, formerly known as hemorrhagic disease of the newborn. Risk factors include home birth, lack of routine neonatal care (no vitamin K prophylaxis), and exclusive breastfeeding (breast milk is low in vitamin K). Vitamin K is essential for the synthesis of factors II, VII, IX, and X. The deficiency leads to a prolonged PT (due to factor VII's short half-life) and eventually a prolonged aPTT. Treatment is administration of vitamin K.

Question 6

1. Administer 4-factor prothrombin complex concentrate with intravenous vitamin K (correct answer)
2. Administer fresh frozen plasma alone, followed by repeat INR in 6 hours
3. Hold warfarin and give 10 mg oral vitamin K only
4. Transfuse one apheresis unit of platelets and monitor for hematoma expansion

Explanation: When you encounter a patient with life-threatening bleeding on warfarin, you need to understand the urgency of coagulopathy reversal. This patient has an acute subdural hematoma with midline shift - a neurosurgical emergency requiring immediate correction of his elevated INR (3.5). The correct approach is A) 4-factor prothrombin complex concentrate (4F-PCC) with intravenous vitamin K. 4F-PCC contains factors II, VII, IX, and X plus proteins C and S, providing immediate reversal of warfarin's anticoagulant effects within minutes. Vitamin K (given IV for fastest onset) restores endogenous factor synthesis over 6-24 hours, preventing rebound anticoagulation as the PCC wears off. B) Fresh frozen plasma alone is inadequate because it requires large volumes (15-20 mL/kg), takes time to thaw and crossmatch, and provides incomplete factor replacement compared to concentrated 4F-PCC. The 6-hour delay is unacceptable in this emergency. C) Holding warfarin with oral vitamin K is far too slow - vitamin K alone takes 12-24 hours for effect, and oral administration is slower than IV. This patient needs immediate reversal for potential neurosurgery. D) Platelet transfusion doesn't address the coagulopathy. His platelet count is normal (210,000/µL), and the bleeding risk stems from warfarin-induced factor deficiency, not thrombocytopenia. Key takeaway: For life-threatening bleeding on warfarin (especially intracranial hemorrhage), always choose rapid reversal with 4F-PCC plus vitamin K. Time is brain tissue in these scenarios.

Question 7

1. Cryoprecipitate to replenish fibrinogen rapidly (correct answer)
2. Desmopressin to enhance von Willebrand factor release
3. Platelets to increase the count above 100,000/µL
4. Prothrombin complex concentrate to replace vitamin K–dependent factors

Explanation: When you encounter postpartum hemorrhage with abnormal coagulation studies, you're dealing with consumptive coagulopathy (DIC). The key is identifying which clotting factor is most critically depleted and needs immediate replacement. This patient's laboratory pattern is classic for DIC: prolonged PT/aPTT, low platelets, markedly elevated D-dimer, and critically low fibrinogen (85 mg/dL, normal 200-400). In obstetric DIC, fibrinogen is typically the first and most severely depleted clotting factor. Since fibrinogen is essential for clot formation, its severe depletion makes effective hemostasis impossible regardless of other interventions. Cryoprecipitate (A) is correct because it's the most concentrated source of fibrinogen available, providing rapid replacement of this critical factor. Each unit contains approximately 250mg of fibrinogen, making it ideal for quickly raising levels above the minimum threshold needed for hemostasis. Desmopressin (B) enhances von Willebrand factor release but won't address the fundamental fibrinogen deficiency causing this bleeding. Platelets (C) are low but not critically so - raising the platelet count won't help if there's insufficient fibrinogen to form clots. Prothrombin complex concentrate (D) replaces vitamin K-dependent factors (II, VII, IX, X) but doesn't contain fibrinogen, which is the rate-limiting factor here. Remember: In obstetric DIC with severe hypofibrinogenemia (<100 mg/dL), cryoprecipitate takes priority over other blood products. Think "fibrinogen first" when you see this constellation of findings with active bleeding.

Question 8

1. High-dose recombinant factor VIII concentrate infusion (correct answer)
2. Intranasal desmopressin to transiently raise factor VIII levels
3. Fresh frozen plasma to supply multiple clotting factors
4. Vitamin K1 (phytonadione) to promote hepatic factor synthesis

Explanation: When you encounter a hemophilia question, focus on the severity of the deficiency and the type of bleeding event. This patient has severe hemophilia A with <1% factor VIII activity and an acute hemarthrosis (joint bleed) - a serious complication requiring immediate, targeted treatment. The correct approach is high-dose recombinant factor VIII concentrate infusion (A). In severe hemophilia A, patients lack sufficient factor VIII for normal clotting. Acute hemarthrosis requires raising factor VIII levels to 80-100% of normal to stop bleeding and prevent permanent joint damage. Only concentrated factor VIII can achieve these therapeutic levels quickly and reliably. Option B (intranasal desmopressin) works by releasing stored factor VIII from endothelial cells, but this patient has <1% baseline activity - there's essentially no factor VIII to release. Desmopressin is only effective in mild hemophilia A where some functional factor VIII exists. Option C (fresh frozen plasma) contains factor VIII but in very low concentrations. You'd need enormous volumes to reach therapeutic levels, risking fluid overload and still likely failing to achieve adequate factor replacement. Option D (vitamin K) promotes synthesis of factors II, VII, IX, and X - the vitamin K-dependent factors. However, factor VIII isn't vitamin K-dependent, and hemophilia A is a genetic deficiency, not a synthesis problem that vitamin K could correct. Remember: severe hemophilia with acute bleeding always requires immediate, high-dose factor replacement with concentrates. Don't be tempted by gentler alternatives when dealing with severe deficiencies and serious bleeding episodes.

Question 9

1. Administer desmopressin 30 minutes before incision and again 12 hours later (correct answer)
2. Transfuse one unit of platelets immediately prior to surgery
3. Start recombinant activated factor VII infusion intra-operatively
4. Give intravenous vitamin K the evening before surgery to normalize aPTT

Explanation: When you encounter perioperative bleeding management questions, focus on matching the hemostatic intervention to the specific underlying disorder and surgical risk level. Von Willebrand disease (vWD) involves deficient or dysfunctional von Willebrand factor, which impairs platelet adhesion and carries factor VIII. The mildly elevated aPTT here reflects decreased factor VIII activity. For type 1 vWD (the mildest form) undergoing intermediate-risk surgery like laparoscopic cholecystectomy, desmopressin (DDAVP) is first-line therapy. Choice A is correct because desmopressin stimulates release of stored von Willebrand factor and factor VIII from endothelial cells, temporarily normalizing hemostasis. The timing (30 minutes pre-op for peak effect) and repeat dosing (12 hours later, as the half-life is 8-12 hours) are appropriate for this surgical timeframe. Choice B is wrong because her platelet count is normal (220,000/µL) and the problem isn't platelet quantity but platelet function due to vWF deficiency. Choice C represents massive overkill - recombinant factor VIIa is reserved for life-threatening bleeding or factor VII deficiency, not routine vWD management. Choice D misunderstands the coagulopathy - the elevated aPTT stems from low factor VIII, not vitamin K deficiency affecting factors II, VII, IX, and X. Remember: DDAVP is your go-to for mild bleeding disorders (type 1 vWD, mild hemophilia A) before elective surgery. It's effective, safe, and avoids blood products. Reserve factor concentrates and aggressive interventions for severe cases or DDAVP failures.

Question 10

1. Discontinue all heparin and initiate intravenous argatroban therapy (correct answer)
2. Continue current heparin infusion and add warfarin with INR goal 2–3
3. Switch to low-molecular-weight heparin at therapeutic dosing
4. Hold anticoagulation entirely until platelet count normalizes

Explanation: When you encounter a patient with suspected heparin-induced thrombocytopenia (HIT), recognize this as a life-threatening prothrombotic condition requiring immediate intervention. HIT typically presents 5-10 days after heparin initiation with a ≥50% platelet drop and paradoxical thrombosis (like the toe discoloration described). The high 4T score confirms strong clinical suspicion. The correct approach is A) Discontinue all heparin and initiate intravenous argatroban therapy. HIT requires immediate cessation of ALL heparin products because continued exposure worsens the immune-mediated platelet activation and thrombosis risk. Argatroban, a direct thrombin inhibitor, provides safe anticoagulation without cross-reactivity to heparin antibodies. B) Continue current heparin infusion and add warfarin is dangerous because continued heparin exposure perpetuates the thrombotic process. Additionally, warfarin alone initially increases thrombosis risk through protein C/S depletion. C) Switch to low-molecular-weight heparin is contraindicated because LMWH has significant cross-reactivity with heparin antibodies in HIT patients, potentially worsening the condition. D) Hold anticoagulation entirely ignores that this patient still has pulmonary embolism requiring continued anticoagulation, plus HIT itself creates a hypercoagulable state demanding immediate alternative anticoagulation. Study tip: Remember "Stop and Swap" for HIT management—immediately stop ALL heparin products and swap to a non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux). Never use LMWH as an alternative in confirmed HIT.

Question 11

1. Transfuse 2 units of fresh frozen plasma immediately prior to the procedure (correct answer)
2. Give 10 mg intravenous vitamin K and delay the line for 24 hours
3. Administer 1 unit of apheresis platelets to raise the count above 100,000/µL
4. No specific therapy is needed; proceed because INR is unreliable in liver disease

Explanation: When you encounter bleeding risk assessment before invasive procedures in cirrhotic patients, you need to balance the coagulopathy against procedural necessity. This patient has severe coagulopathy (INR 2.3, prolonged PT/aPTT) and thrombocytopenia, requiring immediate correction for safe central line placement. Fresh frozen plasma (FFP) is the most appropriate choice here because it provides all coagulation factors that are deficient in liver disease, offering rapid correction of the elevated INR before the urgent procedure. Two units of FFP can typically reduce the INR from 2.3 to a safer range (ideally <1.5) within 30-60 minutes, making option A correct. Option B (vitamin K) is inappropriate because cirrhotic patients have impaired hepatic synthesis of clotting factors, not just vitamin K deficiency. Even with adequate vitamin K, the damaged liver cannot produce sufficient factors, and the 24-hour delay is unacceptable given the urgent need for vasoactive support. Option C addresses the thrombocytopenia, but while platelet count of 68,000/µL is low, it's generally adequate for central line placement (minimum threshold typically 50,000/µL). The coagulopathy poses a greater bleeding risk than the mild thrombocytopenia. Option D reflects a dangerous misconception. While INR may be less predictive of bleeding risk in stable cirrhosis, this patient has acute decompensation with significant coagulopathy that requires correction. Remember: In cirrhotic patients needing urgent procedures, prioritize correcting factor deficiencies with FFP over vitamin K, since the synthetic function is already compromised.

Question 12

1. Idarucizumab, a monoclonal antibody fragment that binds dabigatran (correct answer)
2. Protamine sulfate, which neutralizes dabigatran’s negative charges
3. Vitamin K plus 4-factor PCC to replenish clotting factors
4. Tranexamic acid to inhibit fibrinolysis and control bleeding

Explanation: When you encounter a patient on a direct oral anticoagulant (DOAC) with active bleeding, you need to quickly identify which specific reversal agent matches the medication. DOACs each have targeted reversal strategies that differ from traditional anticoagulants like warfarin or heparin. Dabigatran is a direct thrombin inhibitor, and idarucizumab (choice A) is its specific monoclonal antibody fragment reversal agent. It works by binding directly to dabigatran molecules, neutralizing their anticoagulant effect within minutes. This patient has significant retroperitoneal bleeding with acute kidney injury (creatinine doubled), making rapid reversal crucial since dabigatran is renally eliminated and will accumulate with impaired kidney function. Choice B is incorrect because protamine sulfate reverses heparin by neutralizing its negative charges, but it has no effect on dabigatran's mechanism of direct thrombin inhibition. Choice C represents the reversal strategy for warfarin - vitamin K restores vitamin K-dependent clotting factors, while 4-factor PCC provides immediate factor replacement. However, dabigatran doesn't affect the vitamin K pathway. Choice D, tranexamic acid, is an antifibrinolytic that can help control bleeding but doesn't reverse dabigatran's anticoagulant effect - it's supportive therapy, not a specific reversal agent. Remember the DOAC-specific reversals: idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors (rivaroxaban, apixaban). On Step 2, they'll often test whether you know these targeted therapies rather than defaulting to traditional reversal agents that don't work for newer medications.

Question 13

1. Hold warfarin and give 2.5 mg oral vitamin K to lower the INR safely (correct answer)
2. Continue warfarin at current dose and recheck INR in 3 days
3. Administer IV vitamin K plus 4-factor PCC immediately
4. Stop warfarin permanently and switch to aspirin 81 mg daily

Explanation: When managing supratherapeutic INR on warfarin, your approach depends on the INR level, bleeding risk, and presence of active bleeding. For INRs between 4.5-10 without bleeding, the goal is controlled reversal to avoid both bleeding complications and thrombotic rebound. This patient's INR of 9.2 resulted from a drug interaction—trimethoprim-sulfamethoxazole inhibits warfarin metabolism, dramatically increasing anticoagulation. Since he's asymptomatic without bleeding, you need gradual INR reduction while maintaining some anticoagulation (he still has a mechanical valve). Option A is correct because holding warfarin temporarily plus low-dose oral vitamin K (2.5 mg) provides controlled, predictable INR reduction over 12-24 hours. This prevents bleeding while avoiding complete reversal that could cause valve thrombosis. Option B is dangerous—continuing warfarin with INR >9 significantly increases bleeding risk, especially in an elderly patient. The trimethoprim effect will persist, keeping INR elevated. Option C represents emergency reversal therapy (IV vitamin K plus prothrombin complex concentrate) reserved for active bleeding or urgent procedures. This would completely reverse anticoagulation, creating high thrombotic risk for his mechanical valve. Option D is inappropriate—warfarin remains the optimal anticoagulant for mechanical valves. Aspirin alone provides inadequate protection against valve thrombosis. Key takeaway: For elevated INR without bleeding, match your intervention intensity to the clinical scenario. Always consider why the INR rose (drug interactions are common) and remember that mechanical valves require ongoing anticoagulation—never completely reverse unless actively bleeding.

Question 14

1. Recombinant activated factor VII to bypass the inhibitor (correct answer)
2. High-dose intravenous vitamin K to correct synthetic deficiency
3. Desmopressin to release endogenous factor VIII stores
4. High-dose corticosteroids alone to eradicate the inhibitor before treating bleeding

Explanation: When you encounter a patient with bleeding and an isolated prolonged aPTT that doesn't correct with mixing studies, think acquired factor VIII inhibitor (acquired hemophilia A). This life-threatening condition often develops in elderly patients with malignancies. The key diagnostic clues here are: isolated aPTT prolongation (96 seconds), normal PT and platelet count, failure to correct with 1:1 mixing study (indicating an inhibitor rather than factor deficiency), and severely low factor VIII level (2%). The mixing study distinguishes between factor deficiency (corrects) and inhibitor presence (doesn't correct). For acute bleeding control in acquired hemophilia A, recombinant activated factor VII (choice A) bypasses the factor VIII inhibitor by directly activating factor X, making it the best immediate treatment for life-threatening bleeding. Choice B (vitamin K) treats warfarin overdose or vitamin K deficiency, which would cause prolonged PT, not isolated aPTT prolongation. Choice C (desmopressin) releases endogenous factor VIII stores, but this patient has an inhibitor that would neutralize any released factor VIII, making it ineffective. Choice D (corticosteroids alone) addresses long-term inhibitor eradication but provides no immediate hemostatic control for active bleeding. Strategy tip: For USMLE Step 2, remember the "mixing study rule" - if aPTT corrects with mixing, think factor deficiency; if it doesn't correct, think inhibitor. Acquired hemophilia A requires bypassing agents (factor VIIa or activated prothrombin complex concentrate) for immediate bleeding control, not factor replacement.

Question 15

1. Administer protamine sulfate 1 mg per 1 mg of enoxaparin given, up to a maximum of 50 mg (correct answer)
2. Give intravenous vitamin K 10 mg to facilitate hepatic factor synthesis
3. Infuse fresh frozen plasma to correct anticipated clotting factor depletion
4. No reversal is possible; observe closely and transfuse if bleeding occurs

Explanation: When you encounter enoxaparin overdose questions, focus on the specific reversal mechanisms available for low molecular weight heparins (LMWH) versus unfractionated heparin. Enoxaparin overdose requires prompt reversal when doses are significantly elevated, even without active bleeding, due to the high hemorrhage risk. Protamine sulfate is the antidote of choice for LMWH overdose. However, protamine only partially reverses enoxaparin (about 60-75% neutralization) compared to its complete reversal of unfractionated heparin. The dosing is 1 mg protamine per 1 mg of enoxaparin administered, with a maximum single dose of 50 mg to avoid protamine-related adverse effects. Given this patient received 300 mg enoxaparin only 90 minutes prior, protamine administration is warranted despite the lack of active bleeding. Choice B is incorrect because vitamin K reverses warfarin by facilitating synthesis of vitamin K-dependent clotting factors (II, VII, IX, X), but enoxaparin works by enhancing antithrombin III activity, not by depleting these factors. Choice C is wrong because fresh frozen plasma replaces clotting factors but doesn't neutralize the anticoagulant effect of enoxaparin that's already bound to antithrombin III. Choice D is incorrect because protamine does provide meaningful reversal of LMWH, even if incomplete. Remember that LMWH overdose questions test whether you know protamine works (but incompletely) for enoxaparin, while vitamin K and FFP are distractors that work for warfarin-related bleeding but not heparin products.